HRSA-22-018: Ryan White HIV/AIDS Program Part A HIV Emergency Relief Grant Program
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 52 awards worth $630 million in total. Applications closed on October 6, 2021.
From the official notice on Grants.gov, last changed June 11, 2021. Checked November 7, 2026.
- Total funding$630 million
- Expected awards52
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HRSA-25-054 | July 3, 2024 | Closed October 1, 2024 | Closed |
Key dates
| Posted | June 11, 2021 |
|---|---|
| Deadline | October 6, 2021 |
| Archived by Grants.gov | December 5, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
RWHAP Part A recipients that are classified as an EMA or as a TGA and continue to meet the status as an eligible area as defined in the statute are eligible to apply for these funds. Eligibility for RWHAP Part A grants is based in part on the number of confirmed AIDS cases within a statutorily specified “metropolitan area.” The Secretary uses the Office of Management and Budget’s (OMB) census-based definitions of a Metropolitan Statistical Area (MSA) in determining the geographic boundaries of a RWHAP metropolitan area. HHS utilizes the OMB geographic boundaries that were in effect when a jurisdiction was initially funded under RWHAP Part A. For all newly eligible areas, the boundaries are based on current OMB MSA boundary definitions. For an EMA, this is more than 2,000 cases of AIDS reported and confirmed during the most recent five calendar years, and for a TGA, this is at least 1,000, but fewer than 2,000 cases of AIDS reported and confirmed during the most recent five calendar years for which such data are available. In addition, for three consecutive years, recipients must not have fallen below both the required incidence levels already specified, and required prevalence levels (cumulative total of living cases of AIDS reported to and confirmed by the Director of CDC, as of December 31 of the most recent calendar year for which such data are available). For an EMA, the required prevalence is 3,000 living cases of AIDS. For a TGA, the required prevalence is 1,500 or more living cases of AIDS. However, for a TGA with five percent or less of the total amount from grants awarded to the area under Part A unobligated, as of the end of the most recent FY, the required prevalence is at least 1,400 (and fewer than 1,500) living cases of AIDS. This competition is open to eligible Part A jurisdictions to provide comprehensive primary health care and support services for people with HIV who are low income, uninsured, and underserved in their service areas as listed in Appendix B.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the Ryan White HIV/AIDS Program (RWHAP) Part A HIV Emergency Relief Grant Program. The purpose of this program is to provide direct financial assistance to an eligible metropolitan area (EMA) or a transitional grant area (TGA) that has been severely affected by the HIV epidemic. Grant funds assist eligible jurisdictions to develop or enhance access to a comprehensive continuum of high quality, community-based care for people with HIV who are low-income through the provision of formula, supplemental, and Minority AIDS Initiative (MAI) funds. The goal is to provide optimal HIV care and treatment for people with HIV who are low-income, uninsured, and underserved, to improve their medical outcomes.
Who has won HIV Emergency Relief Project Grants grants before
From fiscal 2021 to 2025, HIV Emergency Relief Project Grants (93.914) awarded $3.5 billion across 140 grant awards, an average of $25.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| City of New York | New York | 2 | $504 million |
| County of Los Angeles | California | 2 | $251 million |
| County of Fulton | Georgia | 2 | $169 million |
| District of Columbia, Government of | District of Columbia | 2 | $161 million |
| Harris County | Texas | 2 | $143 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-22-018 still open?
No. It closed on October 6, 2021.
Who can apply for Ryan White HIV/AIDS Program Part A HIV Emergency Relief Grant Program?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Ryan White HIV/AIDS Program Part A HIV Emergency Relief Grant Program?
Closed October 6, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $630 million in total across about 52 awards.
Who has won HIV Emergency Relief Project Grants grants before?
The largest recipients over five fiscal years were City of New York, County of Los Angeles, County of Fulton. The program made 140 awards worth $3.5 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)